Omeros reports Q3 revenue beat alongside large GAAP loss

Omeros reported third-quarter 2026 YARTEMLEA gross revenue of $41.8M and net revenue of $35.9M, while adjusted EPS was $0.06. GAAP net loss reached $57.4M, driven mainly by a $62.0M non-cash mark-to-market loss tied to convertible-note derivatives, although operating cash flow was positive at $13.3M. The European Medicines Agency also issued a negative opinion on narsoplimab for TA-TMA, and Omeros shares fell 10.4% in after-hours trading.

The earnings print shows commercial growth and positive operating cash flow, but the large non-cash GAAP loss and European regulatory setback created a negative market reaction. Omeros has not provided Q4 2026 or 2027 revenue guidance, while CEO Gregory Demopulos expects Q4 discontinued-operations income of $5M-$6M.

  • 1YARTEMLEA generated $41.8M in gross revenue and $35.9M in net revenue during Q3 2026.
  • 2Omeros reported a Q3 GAAP net loss of $57.4M, or $0.79 per share, including a $62.0M non-cash loss from mark-to-market adjustments on a derivative linked to convertible notes.
  • 3Adjusted EPS was $0.06 versus analyst consensus of $0.01, and gross revenue exceeded the $37.27M estimate.
  • 4Operating cash flow was positive at $13.3M in Q3 2026.
  • 5The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on narsoplimab for TA-TMA after re-examination in October.
  • 6Omeros expects Q4 2026 discontinued-operations income of $5M-$6M, according to CEO Gregory Demopulos.

Sources